234 results on '"Pathil, Anita"'
Search Results
2. Falls and malnutrition are associated with in-hospital mortality in patients with cirrhosis.
3. Hepatic sarcoidosis: Clinical characteristics and outcome
4. Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Variant Syndrome: Clinical Features, Response to Therapy and Long-Term Outcome
5. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
6. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study
7. Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
8. List of Contributors
9. Critical Role of Hepatic Fatty-Acyl Phospholipid Remodeling in Obese and Nonobese Fatty Liver Mouse Models
10. Could inherited predisposition drive non-obese fatty liver disease? Results from German tertiary referral centers
11. Outcomes and costs of treating hepatitis C patients with second-generation direct-acting antivirals: results from the German Hepatitis C-Registry
12. Low frequency of mismatch repair deficiency in gallbladder cancer
13. Prognostic Impact of Carboxylesterase 2 in Cholangiocarcinoma
14. Major histocompatibility complex class I expression impacts on patient survival and type and density of immune cells in biliary tract cancer
15. Diagnostic value of a liver biopsy in patients with an acute liver failure or acute liver injury
16. Hepatic Sarcoidosis: Clinical Characteristics and Outcome
17. SAFETY AND PRELIMINARY EFFICACY AND PHARMACOKINETICS OF INTRAPERITONEAL VS-01 INFUSIONS IN PATIENTS WITH DECOMPENSATED LIVER CIRRHOSIS: A FIRST-IN-HUMAN, OPEN-LABEL, PHASE 1b CLINICAL TRIAL
18. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD
19. Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling
20. Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry
21. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease
22. Comparison of different bile acid–phospholipid conjugates in acute hepatitis
23. Chapter 20 - Critical Role of Hepatic Fatty-Acyl Phospholipid Remodeling in Obese and Nonobese Fatty Liver Mouse Models
24. Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial
25. Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
26. Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy – data from the German hepatitis C registry (DHC-R)
27. Bile salt–phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent#
28. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357
29. Additional file 1: of Programmed cell death ligand 1 (PD-L1, CD274) in cholangiocarcinoma – correlation with clinicopathological data and comparison of antibodies
30. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs : Results from the German hepatitis C registry (DHC-R)
31. Epigenetic Combination Therapy As A Tumor-Selective Treatment Approach for Hepatocellular Carcinoma
32. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL
33. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis
34. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs
35. FRI-208-Predictors of treatment response during addition of pegylated Interferon alfa-2a to an onging nucleos (t)id treatment in chronic hepatitis B: Results from the PADD-ON trial
36. THU-161-Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C treated with DAAs: Results from the German hepatitis C registry (DHC-R)
37. Loss of aquaporin-4 expression and putative function in non-small cell lung cancer
38. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
39. Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study.
40. Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry.
41. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs.
42. Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma
43. Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization
44. Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis
45. Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
46. Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury
47. Circulating Phospholipid Patterns in NAFLD Patients Associated with a Combination of Metabolic Risk Factors
48. Ursodeoxycholyl lysophosphatidylethanolamide negatively regulates TLR-mediated lipopolysaccharide response in human THP-1-derived macrophages
49. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C
50. Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real‐world setting
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.